Sandra and Edward Meyer Cancer Center

A new study from Weill Cornell Medicine provides insights into how cells maintain the tiny end caps of chromosomes as they divide, a key process in keeping cells healthy. Using yeast, the researchers reveal protein interactions that could explain how the enzyme telomerase is tightly regulated to prevent cells from dividing uncontrollably or aging prematurely.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators.

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat “triple negative” breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators. 

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy.

With a mission to understand how nutrition and metabolism impact the body’s ability to control cancer, four leading research institutions have united under the Weill Cancer Hub East, an innovative, collaborative partnership that aims to transform cancer treatment.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. 

Two Weill Cornell Medicine physician-scientists, Dr. Niroshana Anandasabapathy and Dr. Rohit Chandwani, have been elected members of the American Society for Clinical Investigation (ASCI) for 2025.

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine.

Drs. Steven Josefowicz, Ekta Khurana and Kristen Pleil were among 400 early-career scientists and engineers to receive the Presidential Early Career Award for Scientists and Engineers.

In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.

The five-year, $2.3 million grant from the Centers for Disease Control and Prevention will seek to improve equitable access to care, quality of life and survival outcomes for young people with all stages of breast cancer.

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.

Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.

Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Korea’s Yonsei University. 

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition